Clik here to view.
Roth starts NeoGenomics at buy
Roth Capital Partners has initiated coverage of NeoGenomics Laboratories (NASDAQ:NEO) with a “buy” rating and $6 price target. The stock closed at $3.04 on Friday. NeoGenomics is a high-complexity...
View ArticleClik here to view.
Roth starts MacroGenics at buy
Roth Capital Partners has initiated of MacroGenics (NASDAQ:MGNX) with a “buy” rating and $28 price target, saying the “era of molecular engineering is upon us.” The stock closed at $20.03 on Friday....
View ArticleClik here to view.
Roth starts PTC Therapeutics at buy
Roth Capital Partners has initiated coverage of PTC Therapeutics (NASDAQ:PTCT) with a “buy” rating and $34 price target. The stock was quoted at $26.04 at mid-day on Monday. PTC is pioneering the...
View ArticleClik here to view.
Roth upgrades Prosensa Therapeutic to buy
Roth Capital Partners has upgraded Prosensa Therapeutic NV (NASDAQ:RNA) to “buy,” with a $17 price target, reflecting evolving data in the treatment of Duchenne muscular dystrophy (DMD) and a...
View ArticleClik here to view.
Roth starts bluebird bio at buy
Roth Capital Partners has launched coverage of bluebird bio (NASDAQ:BLUE) with a “buy” rating and $50 price target. The stock closed at $36.63 on Friday. “With its proprietary Lentiviral vectors, the...
View ArticleClik here to view.
Roth starts Hyperion Therapeutics at buy
Roth Capital Partners has launched coverage of Hyperion Therapeutics (NASDAQ:HPTX) with a “buy” rating and price target of $34. The stock closed at $24.30 on Friday. “Hyperion is well positioned to...
View ArticleClik here to view.
Roth starts Cortendo AB at buy
Roth Capital Partners has initiated coverage of Cortendo AB (NOTC:CORT; OTC:CRTOF) with a “buy” rating and price target of $3. The stock closed at 97 cents on Thursday. Cortendo is conducting a global...
View ArticleClik here to view.
Roth starts uniQure at buy
Roth Capital Partners has launched coverage of uniQure NV (NASDAQ:QURE) with a “buy” rating and $38 price, saying its AAV-based gene therapy could usher in a new era in the treatment of multiple...
View ArticleClik here to view.
Roth ups Sarepta Therapeutics price target to $50
Roth Capital Partners has raised its price target for Sarepta Therapeutics (NASDAQ:SRPT) to $50 from $45 after the FDA set Feb 26 as the PDUFA date to consider approval of the company’s NDA for...
View ArticleClik here to view.
Roth starts Alcobra Pharma at buy
Roth Capital Partners has launched coverage of Alcobra Pharma (NASDAQ:ADHD) with a “buy” rating and $40 price target. The stock closed at $18.02 on Thursday. Alcobra Pharma’s lead product, MDX, an...
View ArticleClik here to view.
HCW starts Precision BioSciences at buy; PT $21
H.C. Wainwright initiated coverage of Precision BioSciences (NASDAQ:DTIL) with a “buy” rating and $21 price target. The stock closed at $13.76 on July 15. Precision is one of the early adopters of a...
View ArticleClik here to view.
HCW starts Sangamo Therapeutics at buy; PT $16
H.C. Wainwright initiated coverage of Sangamo Therapeutics (NASDAQ:SGMO) with a “buy” rating and $16 price target. The stock closed at $11.02 on Aug. 23. Analyst Debjit Chattopadhyay writes that the...
View ArticleClik here to view.
HCW starts Hookipa Pharma at buy; PT $15
H.C. Wainwright launched coverage of HOOKIPA Pharma (NASDAQ:HOOK) with a “buy” rating and $15 price target. The stock closed at $7.76 on Sept. 26. Hookipa is a developing therapies that leverage its...
View ArticleClik here to view.
HCW starts Stoke Therapeutics at buy; PT $30
H.C. Wainwright launched coverage of Stoke Therapeutics (NASDAQ:STOK) with a “buy” rating and price target of $30. The stock closed at $22.86. Analyst Debjit Chattopadhyay writes that Stoke is...
View ArticleClik here to view.
HCW ups Mersana Therapeutics PT to $12 from $7
H.C. Wainwright raised its price target for Mersana Therapeutics (NASDAQ:MRSN) to $12 from $7, saying the expected data flow, and available activity and safety profile bode well for the company’s...
View ArticleClik here to view.
HCW starts Molecular Partners at buy; PT CHF29
H.C. Wainwright initiated coverage of Swiss-based Molecular Partners (SWX:MOLN) with a “buy” rating and price target of CHF29. The stock closed at CHF17.54 on April 1. Molecular Partners is developing...
View ArticleClik here to view.
HCW starts Bicycle Therapeutics at buy; PT $25
H.C. Wainwright initiated coverage of Bicycle Therapeutics (NASDAQ:BCYC) with a “buy” rating and $25 price target. The stock finished at $14.66 on April 17. The company is focused on bicycles, which...
View Article
